Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Dufek

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The New England Journal of Medicine|February 14, 2024
Inhibition of CD40L with Frexalimab in Multiple SclerosisPatrick Vermersch, Cristina Granziera, Yang Mao-Draayer, et al.
Frontiers in Neurology|March 4, 2024
Case report: Susac syndrome-two ends of the spectrum, single center case reports and review of the literatureMartina Cviková, Jakub Štefela, Vít Všianský, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2011
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Neurology|April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II StudyScott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Journal of Central Nervous System Disease|July 26, 2024
Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registryPavel Potuznik, Jiri Drahota, Dana Horakova, et al.
Multiple Sclerosis and Related Disorders|June 22, 2023
Is breastfeeding in MS harmful or not? An answer from real-world Czech dataPavel Hradilek, Olga Zapletalova, Petra Hanulikova, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 28, 2023
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021Dominika Stastna, Jiri Drahota, Michal Lauer, et al.
Multiple Sclerosis and Related Disorders|June 17, 2023
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registriesTereza Hrnciarova, Jiri Drahota, Tim Spelman, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The New England Journal of Medicine|February 14, 2024
Inhibition of CD40L with Frexalimab in Multiple SclerosisPatrick Vermersch, Cristina Granziera, Yang Mao-Draayer, et al.
Frontiers in Neurology|March 4, 2024
Case report: Susac syndrome-two ends of the spectrum, single center case reports and review of the literatureMartina Cviková, Jakub Štefela, Vít Všianský, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2011
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Neurology|April 17, 2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II StudyScott D Newsome, Ewa Krzystanek, Krzysztof W Selmaj, et al.
Journal of Central Nervous System Disease|July 26, 2024
Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registryPavel Potuznik, Jiri Drahota, Dana Horakova, et al.
Multiple Sclerosis and Related Disorders|June 22, 2023
Is breastfeeding in MS harmful or not? An answer from real-world Czech dataPavel Hradilek, Olga Zapletalova, Petra Hanulikova, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|April 28, 2023
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021Dominika Stastna, Jiri Drahota, Michal Lauer, et al.
Multiple Sclerosis and Related Disorders|June 17, 2023
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registriesTereza Hrnciarova, Jiri Drahota, Tim Spelman, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
Pageof 2